Melphalan

Generic Name
Melphalan
Brand Names
Alkeran, Evomela, Phelinun, Pepaxti
Drug Type
Small Molecule
Chemical Formula
C13H18Cl2N2O2
CAS Number
148-82-3
Unique Ingredient Identifier
Q41OR9510P
Background

Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...

Indication

Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...

Associated Conditions
Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

First Posted Date
2019-01-30
Last Posted Date
2024-05-16
Lead Sponsor
University of Birmingham
Target Recruit Count
242
Registration Number
NCT03821610
Locations
🇬🇧

Cardiff and Vale University Health Board, Cardiff, United Kingdom

🇬🇧

The Clatterbridge Cancer Centre Nhs Foundation Trust, Liverpool, United Kingdom

🇬🇧

University Hospitals of Leicester Nhs Trust, Leicester, United Kingdom

and more 19 locations

BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma

First Posted Date
2019-01-04
Last Posted Date
2019-01-07
Lead Sponsor
Soonchunhyang University Hospital
Target Recruit Count
75
Registration Number
NCT03794167
Locations
🇰🇷

Jong-Ho Won, Seoul, Korea, Republic of

Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)

First Posted Date
2019-01-03
Last Posted Date
2019-01-04
Lead Sponsor
Soonchunhyang University Hospital
Target Recruit Count
51
Registration Number
NCT03792815
Locations
🇰🇷

Soonchunhyang University Hospital, Seoul, Korea, Republic of

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

First Posted Date
2018-12-26
Last Posted Date
2024-10-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
42
Registration Number
NCT03786783
Locations
🇺🇸

Saint Jude Children's Research Hospital, Memphis, Tennessee, United States

🇳🇿

Starship Children's Hospital, Grafton, Auckland, New Zealand

🇦🇺

The Children's Hospital at Westmead, Westmead, New South Wales, Australia

and more 7 locations

Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

First Posted Date
2018-11-15
Last Posted Date
2022-09-14
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
462
Registration Number
NCT03742297
Locations
🇪🇸

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

🇪🇸

Hospital Universitario de Cruces, Bilbao, Spain

🇪🇸

Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain

and more 55 locations

Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

First Posted Date
2018-11-09
Last Posted Date
2022-07-22
Lead Sponsor
Swedish Medical Center
Target Recruit Count
47
Registration Number
NCT03736616
Locations
🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

First Posted Date
2018-10-01
Last Posted Date
2024-03-12
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
4
Registration Number
NCT03691376
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

First Posted Date
2018-09-17
Last Posted Date
2024-04-10
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
22
Registration Number
NCT03674411
Locations
🇺🇸

Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

First Posted Date
2018-08-03
Last Posted Date
2024-03-12
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
9
Registration Number
NCT03615105
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

First Posted Date
2018-08-03
Last Posted Date
2021-03-24
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
1
Registration Number
NCT03615144
Locations
🇺🇸

Memorial SloanKettering Cancer Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy